Literature DB >> 18502012

Predictors of the course of illness in outpatients with schizophrenia: a prospective three year study.

J M Haro1, D Novick, D Suarez, S Ochoa, M Roca.   

Abstract

The course of schizophrenia includes a combination of periods of remission and relapse. Previous studies focused on simple dichotomous outcomes and did not take into account the complexity of the course. Using data from a large 3-year follow-up study of schizophrenia, we described the different courses of schizophrenia. Of the 5950 patients with complete 3-year data, 38.7% never achieved remission (prolonged course), 15.7% achieved remission but relapsed and 45.7% achieved and maintained remission (persistent remission). Females, patients with better social functioning at baseline (living independently, in paid employment, socially active or having a spouse or partner) and with a shorter duration of illness had a more favourable course. Patients prescribed risperidone, quetiapine or depot typicals at the baseline visit were more likely to have a prolonged course than patients who started olanzapine. The results show that description of the long-term outcome of schizophrenia cannot be summarized with just one outcome variable.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18502012     DOI: 10.1016/j.pnpbp.2008.04.003

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  17 in total

Review 1.  Pharmacogenetics of response to antipsychotics in patients with schizophrenia.

Authors:  Maria J Arranz; Margarita Rivera; Janet C Munro
Journal:  CNS Drugs       Date:  2011-11-01       Impact factor: 5.749

2.  Complex interaction between symptoms, social factors, and gender in social functioning in a community-dwelling sample of schizophrenia.

Authors:  F Vila-Rodriguez; S Ochoa; J Autonell; J Usall; J M Haro
Journal:  Psychiatr Q       Date:  2011-12

3.  Using World Health Organization Disability Assessment Schedule 2.0 in people with schizophrenia: a 4-year follow-up.

Authors:  Ruey Chen; Tsan-Hon Liou; Nae-Fang Miao; Kwang-Hwa Chang; Chia-Feng Yen; Hua-Fang Liao; Wen-Chou Chi; Kuei-Ru Chou
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-04-22       Impact factor: 5.270

4.  Family Functioning in First-Episode and Chronic Psychosis: The Role of Patient's Symptom Severity and Psychosocial Functioning.

Authors:  Katerina Koutra; Sofia Triliva; Theano Roumeliotaki; Maria Basta; Christos Lionis; Alexandros N Vgontzas
Journal:  Community Ment Health J       Date:  2015-08-19

5.  Psychosocial disabilities in patients with schizophrenia.

Authors:  Ma Goreishizadeh; A Mohagheghi; S Farhang; L Alizadeh
Journal:  Iran J Public Health       Date:  2012-05-31       Impact factor: 1.429

6.  The heterogeneity of antipsychotic response in the treatment of schizophrenia.

Authors:  M Case; V L Stauffer; H Ascher-Svanum; R Conley; S Kapur; J M Kane; S Kollack-Walker; J Jacob; B J Kinon
Journal:  Psychol Med       Date:  2010-10-07       Impact factor: 7.723

7.  The importance of measuring psychosocial functioning in schizophrenia.

Authors:  Sofia Brissos; Andrew Molodynski; Vasco Videira Dias; Maria Luísa Figueira
Journal:  Ann Gen Psychiatry       Date:  2011-06-24       Impact factor: 3.455

8.  Systematic review of the economic aspects of nonadherence to antipsychotic medication in patients with schizophrenia.

Authors:  Tatiana Dilla; Antonio Ciudad; María Alvarez
Journal:  Patient Prefer Adherence       Date:  2013-04-04       Impact factor: 2.711

Review 9.  Long-acting antipsychotic drugs for the treatment of schizophrenia: use in daily practice from naturalistic observations.

Authors:  Giuseppe Rossi; Sonia Frediani; Roberta Rossi; Andrea Rossi
Journal:  BMC Psychiatry       Date:  2012-08-21       Impact factor: 3.630

10.  The social functional outcome of being naturalistically treated with paliperidone extended-release in patients with schizophrenia.

Authors:  Ryoko Nakagawa; Takashi Ohnishi; Hisanori Kobayashi; Akihide Wakamatsu; Ai Tanimura; Kazuo Morita; Toshio Yamaoka; Hideo Usui; Yoshimasa Ogawa; Akiko Fujino; Kazutake Yoshizawa
Journal:  Neuropsychiatr Dis Treat       Date:  2015-06-22       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.